
Stanley Capital-Backed Portfolio Company DSS Acquires MyMeds&Me
Newly combined organization to provide pharmacovigilance solution focused on current and future requirements of the life sciences industry.
Stanley Capital Partners LLP (SCP) announced the acquisition of MyMeds&Me Limited (MMM) by its portfolio company Drug Safety and Pharmacovigilance Services Solutions (DSS). DSS is a global provider of pharmacovigilance services under the brand Bioclinica. The financial terms of the transaction are not being disclosed.
The combined, digital-first organization will provide a pharmacovigilance solution focused on the current and future requirements of the life sciences industry.
Read more about the acquisiton
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.